After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, XENE falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Xenon Pharmaceuticals Inc is $2.98B. A total of 0.59 million shares were traded on the day, compared to an average of 402.79K shares.
In the most recent transaction, GAROFALO ELIZABETH A. sold 2,092 shares of XENE for 45.69 per share on Mar 08 ’24. After the transaction, the Director now owns 0 company shares. In a previous transaction on Mar 07 ’24, ROBIN SHERRINGTON sold 7,137 shares at 46.28 per share. XENE shares that EVP, Strategy & Innovation owns now total 8,398.
Among the insiders who sold shares, GANNON STEVEN disposed of 13,000 shares on Mar 07 ’24 at a per-share price of $46.28. This resulted in the Director holding 2,000 shares of XENE after the transaction. In another insider transaction, PATOU GARY sold 11,380 shares at $39.29 per share on Dec 13 ’23. Company shares held by the Director now total 23,573.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, XENE has a high of $50.99 and a low of $27.99.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. XENE’s latest balance sheet shows that the firm has $551.77M in Cash & Short Term Investments as of fiscal 2021. There were $8.26M in debt and $14.32M in liabilities at the time. Its Book Value Per Share was $11.15, while its Total Shareholder’s Equity was $550.03M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XENE is Buy with a score of 4.88.
